Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SSGJ 706

Next Previous
Drug Profile

SSGJ 706

Alternative Names: 706 anti-PD1/PD-L1 Bispecific antibody; 706 anti-PD1/PD-L1 BsAb; 706-3SBio; SSGJ-706

Latest Information Update: 20 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3SBio
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastrointestinal cancer

Most Recent Events

  • 18 Nov 2025 Shenyang Sunshine Pharmaceutical plans a phase II trial for Gastrointestinal cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable) in China (IV) (NCT07233850)
  • 24 Oct 2025 Phase-II clinical trials in Non-small cell lung cancer (First-line therapy, Metastatic disease, Late-stage disease, Combination therapy) in China (Parenteral) (NCT07171606)
  • 24 Oct 2025 Phase-II clinical trials in Non-small cell lung cancer (First-line therapy, Monotherapy, Metastatic disease, Late-stage disease) in China (Parenteral) (NCT07171606)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top